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Abstract
Background: Chlamydia trachomatis is the most common bacterial sexually transmitted infection (STI) in the United
States (U.S.) [1] and remains a major public health problem. We determined the cost- benefit of screening all pregnant
women aged 15–24 for Chlamydia trachomatis infection compared with no screening.
Methods: We developed a decision analysis model to estimate costs and health-related effects of screening pregnant
women for C. trachomatis in a high burden setting (Brooklyn, NY). Outcome data was from literature for pregnant
women in the 2015 US population. A virtual cohort of 6,444,686 pregnant women, followed for 1 year was utilized.
Using outcomes data from the literature, we predicted the number of C. trachomatis cases, associated morbidity, and
related costs. Two comparison arms were developed: pregnant women who received chlamydia screening, and those
who did not. Costs and morbidity of a pregnant woman-infant pair with C. trachomatis were calculated and compared.
Results: Cost and benefit of screening relied on the prevalence of C. trachomatis; when rates are above 16.9%, screening
was proven to offer net cost savings. At a pre-screening era prevalence of 8%, a screening program has an increased
expense of $124.65 million ($19.34/individual), with 328 thousand more cases of chlamydia treated, and significant
reduction in morbidity. At a current estimate of prevalence, 6.7%, net expenditure for screening is $249.08 million ($38.
65/individual), with 204.63 thousand cases of treated chlamydia and reduced morbidity.
Conclusions: Considering a high prevalence region, prenatal screening for C. trachomatis resulted in increased
expenditure, with a significant reduction in morbidity to woman-infant pairs. Screening programs are appropriate if the
cost per individual is deemed acceptable to prevent the morbidity associated with C. trachomatis.
Keywords: C. trachomatis, Chlamydia screening, Pregnant women
Background
Chlamydia trachomatis is the most common bacterial
sexually transmitted infection (STI) in the United States
(U.S.) [1] and remains a major public health problem. In
2010, there were >1.3 million infections in the U.S. re-
ported to the Centers for Disease Control (CDC) [2]. In
2013, the estimated direct lifetime cost of treatment for
chlamydia and complications was > $500 million [3].
The majority of most genital chlamydia infections in
women are asymptomatic [1]. Untreated infection in
women can result in pelvic inflammatory disease (PID),
which can cause infertility, ectopic pregnancy, and chronic
pelvic pain. In addition, infants born to women with un-
treated chlamydial infection may acquire infection during
delivery which can lead to neonatal conjunctivitis and re-
spiratory tract infection [1]. Untreated infections in men
can lead to urethritis, epididymitis, proctitis and Reiter’s
syndrome [4]. Thus, screening is needed to identify and
treat infections before complications develop [5].
Although several studies have investigated the cost-
effectiveness of chlamydia screening for non-pregnant
* Correspondence: tamar.smith-norowitz@downstate.edu
Department of Pediatrics, Division of Infectious Diseases, State University of
New York Downstate Medical Center, Box 49450 Clarkson Ave, Brooklyn, NY
11203, USA
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Ditkowsky et al. BMC Infectious Diseases  (2017) 17:155 
DOI 10.1186/s12879-017-2248-5
women [6], few studies have examined the cost-benefit
of chlamydia screening in antenatal clinics [5, 7]. Cur-
rently prenatal screening for C. trachomatis and treat-
ment of pregnant women is part of routine antenatal
care in only a few countries globally, including the
United States, Canada, Japan, and Germany [8]. One of
the major reasons given for why prenatal screening has
not been implemented in other countries, including the
Netherlands and United Kingdom, is that it is not cost-
effective [9]. Routine screening for C. trachomatis in
pregnant women in the US was recommended by the
Centers for Disease Control and Prevention in 1993
[10]. Annual screening of all sexually active women aged
<25 years is recommended, as is screening of older
women at increased risk for infection (e.g., those who
have a new sex partner, more than one sex partner, a sex
partner with concurrent partners, or a sex partner who
has a sexually transmitted infection) [11]. The purpose
of this study was to model the cost-benefit of C. tracho-
matis screening all pregnant women, 16–25 years of age,
compared with no screening in an area with a high
prevalence of chlamydia infection (Brooklyn, New York).
We hypothesized that the implementation of Chlamydia
screening program will avert significant morbidity, des-
pite net cost expenditure.
Methods
Model parameters and primary analysis
A decision analysis model using TreeAge Prosuite 2014
software (TreeAge Software, Williamstown, MA.) was
developed to assess two study arms: 1) Chlamydia
screening in pregnant women and 2) No chlamydia
screening in pregnant women. The model’s variables
were set to mimic the characteristics of the 2015 U.S.
national population for a virtual cohort of 6,444,686
pregnant women (approximate number of pregnancies
in 2015) (ages 15–24). The model predicted the costs to
the healthcare system and morbidity associated with
screening for chlamydia over the course of 1 year. End-
points included direct costs to health care system, rates
of vertical transmission to infant, PID, spontaneous
abortion associated with chlamydial infection, neonatal
conjunctivitis, neonatal chlamydial pneumonia, preterm
delivery and rates of treated chlamydia.
Population and disease parameters were set as point
estimates, using 2015 United States Dollars (USD). The
model was run using three different estimates for chla-
mydia prevalence in a high burden (increased chlamydial
prevalence) US setting (Brooklyn, NY): 8% (pre-screening
era) [12], 6.7% (current prevalence), and 16.9% (threshold
prevalence at which costs associated with screening equal
that of a “no screening” scenario) [12–14]. The base case
analysis assumed a 100% screening rate with 98% sensitiv-
ity for chlamydia. Alternate screening rates were examined
in sensitivity analyses. Rates of morbidity associated with
chlamydia infection concurrent with pregnancy were set
to the most recent estimates available. This study was ex-
empt from ethical approval since we used existing data or
record collection from prior literature that contained non-
identifiable data about humans.
Costs and disease parameters
The decision analysis model examined direct costs to
the health-care system associated with chlamydia screen-
ing and infection during pregnancy. Costs associated
with chlamydia screening were derived from current
Medicaid reimbursement rates. Health-care related costs
associated with morbidity were derived predominantly
from previous cost-effective analysis addressing sequelae
of chlamydial infection.
Chlamydia prevalence was gathered from pre-screening
and current estimates of prevalence in Brooklyn, NY [12].
Rates of morbidity including vertical transmission, PID,
spontaneous abortion associated with chlamydial infec-
tion, neonatal conjunctivitis, neonatal chlamydial pneu-
monia and preterm delivery were derived both from
primary epidemiological studies [12] and previous cost-
effective analyses. Costs and disease parameters are listed
in Table 1.
Epidemiological model
Identical cohorts of pregnant women were placed into a
“Screening” or “No Screening” group. Individuals could
either be chlamydia positive or negative. Those in the
“Screening” scenario either received or forewent screen-
ing, with a sensitivity of 98% for those screened [15].
Chlamydia positive individuals in either group could be
asymptomatic, treated, or lost to follow up. If lost to
follow-up, or with treatment failure, individuals could
receive no sequelae, or enter a morbidity branch includ-
ing vertical transmission, PID, spontaneous abortion
endpoints could exist in a single individual. As hypothet-
ical cohort members entered different branches, they ac-
crued costs associated with screening and each
aforementioned endpoint. Rates of morbidity and costs
to the health-care system were recorded as they were ac-
cumulated. Samples from the decision analysis tree are
presented in Figs. 1 and 2.
Primary analysis
The primary analysis considered a pre-screening preva-
lence of 8% with an assumed screening rate of 100%
[12]. It predicted absolute and net costs to the health-
care system, as well as morbidity in either scenario. The
analysis was conducted with a post-screening era mod-
ern prevalence of 6.7% [14]. Additionally, a threshold
analysis that examined outcomes at a prevalence in
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which costs associated with screening equaled that of a
“No Screening” scenario was performed.
Sensitivity analysis
Sensitivity analyses were conducted for all variables
present in the model, varied across published ranges or
set to +/-50% of the base case parameter. In-depth ana-
lyses were performed for key variables including rates of
untreated chlamydia, cost of chlamydia screening, and
rates of screening coverage. A multiway probabilistic ana-
lysis, in which those three variables were simultaneously
varied across a certain distribution, was conducted. These
variables were distributed across a triangular distribution,
with the base case being most likely and the end of the
ranges set to +/-50% of the base variable. The distribution
for screening coverage was set between 50–100%. The
multiway probabilistic analysis consisted of 100 runs and
100,000 μ simulations. Sensitivity analyses were conducted
with a base chlamydia pre-screening prevalence of 8%.
Results
Primary analysis
Considering a cohort of 6,444,686 pregnant women in
the 2015 US population in the base case analysis of a
100% screening rate with 8% prevalence of chlamydia
[12], the model estimated a screening program would
cost $256.305 million dollars per year to the healthcare
system including screening and treatment expenses, and
result in 496,000 treated cases of chlamydia. In a “No
Screening” scenario, there is an estimated cost of $131.655
million, result in 168,000 treated cases of chlamydia. Ul-
timately, the model estimates that a screening program
would result in an increased expense of $124.65 million,
with 328,000 more cases of chlamydia treated. This calcu-
lates out to $19.34 per screened individual. Other esti-
mated morbidities are shown in Table 2.
Using a post-screening modern prevalence estimate of
6.7% [13], there was an estimated net increase in ex-
penditure of $142.660 million, with 204,630 cases of
treated chlamydia. This leads to $22.14 per screened
individual. A threshold analysis was conducted that exam-
ined the prevalence at which the cost of screening equaled
the costs averted, a prevalence of 16.9%. At this preva-
lence, the cost associated with both scenarios is $279.158
million, with 696,000 treated cases of chlamydia. All other
estimates of morbidity are shown in Table 2.
Sensitivity analysis
Parameters affecting the health-related outcomes and
costs associated with chlamydia in a screening and non-
screening scenario were varied, either by +/-50% of their
base value, across published ranges, or to encompass a
wide variety of values. All variables were tested, and
those with significant impact on outcomes are reported.
In all situations, the cost of screening outweighed the
cost of no screening, but significant morbidity was con-
sistently averted (Table 3). When the cost of chlamydia
screening was reduced by 50%, net cost expenditure was
lowest, at $16.4 million, $2.55 per screened individual.
The percent of individuals screened for chlamydia was
varied between 60–100%, in 10% intervals, as part of the
sensitivity analysis, with 100% acting as the primary ana-
lysis reported above. When decreased to 60%, net cost
expenditures were $51.235 million. Significant morbidity
associated with the model’s endpoints was still averted,
as reported in Table 4.
Table 1 Disease epidemiological and cost data
Value Reference
Chlamydia Prevalence .08/6.7 [12, 14]
NAAT chlamydia screen
Sensitivity 0.98 [15]




Success Rate 0.97 [31]
Cost a $1.86 [16]
PID
Prevalence 0.27 [32]











Cost a $83.23 [5]
Neonatal pneumonia
Prevalence 0.16 [12]





Infertility associated with PID .123 [37]
Prevalence 0.33 [38]
Cost a $6060.82 [39, 40]
Values and costs associated with each variable in the model
NAAT nucleic acid amplification test, PID pelvic inflammatory disease
aCosts expressed in 2015 USD
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Monte Carlo multiway probabilistic analysis
A Monte Carlo multiway probabilistic sensitivity ana-
lysis was conducted to offer end-point variable preci-
sion similar to a true approximate randomization test,
and to offer an efficient implementation of hypothesis
tests. In this analysis four variables with the greatest im-
pact on outcomes were varied according to a triangular
distribution of +/-50%, or across the range used in the
one-way sensitivity analysis. These included: 1) probability
of receiving chlamydia treatment without screening, 2)
percent of population covered by screening 3) the cost of
chlamydia screening and 4) chlamydia prevalence. The ab-
solute cost of a screening program was then tested. The
median cost was $254.565 million associated with a
screening program, with a mean of $243.958 million. The
interquartile range was $228.127 million - $260.439 mil-
lion. There were no iterations out of the 100 run in which
costs associated with a screening program were lower
than that of a non-screening scenario (Fig. 3).
Discussion
Based on our decision analysis model, the total an-
nual health care cost associated with chlamydia is
greater when a screening program is implemented in
both high and low burden settings. However, there is
a significant decrease in chlamydia associated mor-
bidity, which may offset the increased cost of screen-
ing given an appropriate willingness-to-pay (WTP).
These results are consistent with several prior cost-
effective models that show increased cost of chla-
mydia screening, often offset by quality adjusted life
(QALY) units and monetary conversion, with a not-
able decrease in associated morbidity [3, 5, 16, 17].
Current US guidelines recommend screening for
chlamydia in early pregnancy despite a distinct lack
of evidence as to outcomes [18]. Since these recom-
mendations were set knowing there is likely no net
cost savings associated with chlamydia screening, the
averted morbidity reported is of primary importance.
Main findings
The findings from the current investigation may offer
guidance as to the future recommendations for chla-
mydia screening in both high and low burden settings.
Despite increased cost expenditures, the cost thresh hold
necessary to implement a program is low per individual,
at $19.34 considering an 8% prevalence rate. The sugges-
tion that this is a low cost per individual is pronounced
Fig. 2 Sample of Post-Chlamydia Infection Decision Tree: Figure displays a simplified breakdown of the decision tree used to determine morbidity
and costs associated with chlamydia in a pregnant woman Circle: chance node; Triangle: terminal node
Fig. 1 Decision Tree Study Arms: Sample of decision tree displaying the two study arms, slightly modified: A scenario in which pregnant women
are screened for chlamydia, and a scenario in which no screening program exists. Square: origin node; Circle: chance node; Triangle: terminal node
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when compared values for other STI screening recom-
mendations such as that for Hepatitis B, which is esti-
mated to cost $75.45 per individual when screening
pregnant women in the US [19]. It is important to men-
tion that in this study, screening was shown to signifi-
cantly decrease major chronic sequelae of chlamydia
such as infertility. Rates decreased by almost 400%,
which translates to large absolute numbers, particularly
in high burden populations. This can be further extrapo-
lated to account for QALYs saved for neonates when
chlamydia-associated infertility and subsequent inability
to carry a pregnancy is averted. Consequently, concerns
regarding the cost associated with chlamydia screening for
pregnant women, particularly as they apply to high burden
settings, may be abated by monetary values revealed in
this model when compared to other accepted programs.
Previous studies in our laboratory examined incidence
and treatment outcomes of chlamydial conjunctivitis in
the prescreening era offer support for our model’s re-
sults. Hammerschlag, et al. [12] reported in a vertical
transmission data study that prenatal screening and
treatment of pregnant women was the most effective
way to prevent neonatal chlamydial infections, especially
as neonatal ocular prophylaxis has not been demon-
strated to be effective in prevention of neonatal chla-
mydia conjunctivitis [12, 20]. These results may also be
relevant to other endpoints found in our model, and of-
fers support for the importance of a screening program
by reducing neonatal chlamydia-associated morbidity, as
evidenced in the present study [12].
Ong, et al [5], in a study from Australia, found that
antenatal screening of women aged 16–25 is likely to be
cost-effective with significantly reduced morbidity. The
findings from our current decision analysis model are in
agreement with the aforementioned studies. Further-
more, Ong, et al [5] agree with the current analysis that
although there is net cost expenditure at predicted levels
of chlamydia prevalence, infection rates rise cost savings
quickly outpace expenditures [5]. These results hold true
despite using prevalence and vertical transmission data
gathered through two different methodologies. Ong et al
[5] reported prevalence rates that were gathered from
Australian family planning clinic records, and vertical
transmission data was gathered from previously pub-
lished studies in other populations [5]. The prevalence
rates used in the current study were based on screening
of over 4,000 pregnant women in one medical center in
central Brooklyn [12]. Furthermore, vertical transmission
data was based on screening 4357 pregnant women for
cervical chlamydial infection, of whom 341 (8%) had
positive cultures [12]; 230 of their infants were for
followed for 3 months and evaluated for development of
neonatal chlamydial conjunctivitis, pneumonia and naso-
pharyngeal infection with serial cultures. Additionally,
the rate of chlamydia infection among women less than
18 years of age was 14% [12]. Despite values for these
important variables coming from two different method-
ologies (Ong et al. [5] and direct screening in the
current study), the results remained grossly similar
notwithstanding expected differences in exact num-
bers and ranges.
In the current investigation the increased cost associ-
ated with screening as determined by our model
does not consider the long-term effect of decreasing
Table 2 Primary analysis
Screened for Chlamydia No screening
8% Prevalence
Cost§ 256,305,162 131,664,935
Treated Chlamydia 496,241 167,562
PID 6393 23,658
SAB 3 10
Vertical Transmission 8211 37,050







Treated Chlamydia 204,632 66,819
PID 2673 9852
SAB 3 9
Vertical Transmission 4999 15,427







Treated Chlamydia 1,044,039 348,013
PID 6528 49,985
SAB 6 21
Vertical transmission 9757 78,264





PID pelvic inflammatory disease, SAB spontaneous abortion, WTP willingness
to pay
§2015 USD
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prevalence of chlamydia in a population. Through com-
parison of results using the pre-screening prevalence of
chlamydia (8%) to those of the post-screening modern
era (6.7%), it appears as though a modern screening pro-
gram results in a lower decrease in chlamydia-associated
morbidity with a large increase in net cost, as compared
to a non-screening scenario [21]. Although these results
are accurate for areas with a similar or otherwise low
burden prevalence rate that have yet to implement a
screening program, or implemented one despite a low
prevalence rate, this does not hold true for areas with a
high prevalence prescreening. In a situation with a high
prevalence pre-screening that has, as a consequence of
screening, decreased its prevalence rate, there is signifi-
cant cost savings and decline in morbidity associated
with a decrease in prevalence rates. As such, the esti-
mates revealed in this model likely underestimate true
cost savings and morbidity decline associated with the
long-term implementation of a chlamydia screening pro-
gram [21].
Currently, there are no systemic review studies that
have investigated the effect of chlamydia screening spe-
cifically in pregnant women. However, the United States
Preventive Services Task Force (USPSTF) recommends
screening for chlamydia in early pregnancy. Current
guidelines also recommend screening in early pregnancy
for other sexually transmitted infections (STIs) including
HIV, gonorrhea and Hepatitis B [18]. Similarly, little evi-
dence exists for clinical outcomes associated with
screening for these STIs, particularly in pregnancy.
However given the low harm, high potential benefit and
relatively low cost associated with screening for these
STIs, as evidence by this model and other similar
models, early screening for STIs during pregnancy has
been determined to be an acceptable use of healthcare
resources [18].
Table 3 Sensitivity analysis
Screening No Screening
Treatment Rate w/o Screening −50% (±)50% −50% (±)50%
Costa 256,369,609 256,047,375 154,543,570 109,301,875
SAB 3 2 5 15
Pneumonia 3106 3061 16,769 10,486
PID 6574 5298 29,194 18,258
Neonatal Conjunctivitis 7321 6284 36,702 22,969
Vertical Transmission 9564 7495 45,777 28,537
Treated Chlamydia 470,462 541,354 83,781 244,898
Premature 3 2 7 4
Infertility 815 657 3620 2264
Cost of Chlamydia Screening
Costa 148,098,884 363,222,503 131,664,935 131,664,935
Outcomes of all endpoints when the values of high impact variables were varied over a range of +/-50% of base value
SAB spontaneous abortion, PID pelvic inflammatory disease
aCosts expressed in 2015 USD
Table 4 Screening coverage rate
100% (base case analysis) 90% 80% 70% 60%
Cost a 256,305,162 245,671,430 221,104,287 207,838,030 182,900189
SAB 3 32 38 49 54
Pneumonia 3,093 3,351 4,021 5,027 5,530
PID 6,393 6,896 7,585 8,344 9,467
Neonatal Conjunctivitis 6,806 7,366 8,471 9,318 10,996
Vertical Transmission 8,211 8,533 9,642 10,563 12,042
Treated Chlamydia 496,241 431,794 362,707 333,690 296,941
Premature 3 28 31 36 43
Infertility 380 841 925 1,111 1,155
Outcomes of all endpoints when the % of total women screened by program was varied between 60–100%
SAB spontaneous abortion, PID pelvic inflammatory disease
aCosts expressed in 2015 USD
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Prenatal screening and treatment is more effective
than other control methods, specifically, neonatal ocular
prophylaxis. Hammerschlag, et al [12] demonstrated that
neonatal ocular prophylaxis with erythromycin or tetra-
cycline ophthalmic ointments was ineffective for preven-
tion of chlamydial ophthalmia in infants, as well as
having no effect on respiratory infection [12]. The Can-
adian Pediatric Society recently recommended that
neonatal ocular prophylaxis for C. trachomatis infection
be stopped, and emphasized the importance of prenatal
screening and treatment [22, 23]; Currently, the
American Academy of Pediatrics (AAP) is considering a
program similar to that in Canada. Prenatal screening
may be an important public health intervention in low
resource areas, especially when, affordable, sensitive
NAAT based screening tests become available. It should
also be mentioned that some countries that currently do
not screen actually have high prevalence of C. trachoma-
tis infection (>8%) in some of their populations, includ-
ing the Netherlands (8%) [24] and Ireland (5.6% overall,
9.1% in women 16–18 years of age) [25].
Several advantages to expanding or initiating chla-
mydia screening programs outside of averted morbidity
exist. It is possible, that with increased screening a
higher burden of chlamydia in the population will be
discovered, revealing the program to be increasingly
cost-effective. Furthermore, since programs can be rolled
out into already present antenatal care schedules, there
is a decreased cost associated with administration, as
well as decreased indirect costs to the patient. Sexual
histories can be unreliable when determining the clinical
risk of chlamydia infection, an opt-out approach to
screening can avoid this uncertainty altogether [5].
Finally, identification of an infected mother offers the
opportunity to provide treatment for sexual partner to
help prevent re-infection and chlamydia-associated mor-
bidity in the partner.
Strengths and limitations
Strengths of this study included our ability to base our
cost estimates and disease parameters from published
studies without assumptions and with few calculated es-
timates. Those estimates that were calculated utilized
linear regression between data points or simple algebra.
Most epidemiological and cost data came from U.S.
sources, adding to the accuracy of the results. Addition-
ally, using data available in the literature, we were able
to examine numerous endpoints associated with the
health of both the pregnant woman and fetus/newborn.
We were able to focus our study on a high burden set-
ting and examine the effect of a screening program at
two point prevalences: at implementation, and many
years later after a screening program has been able to
affect infection rate. Finally, it should be mentioned that
given the accuracy of the data based in strong epidemi-
ology, and robustness of our results in the setting of sen-
sitivity analyses, this study is generalizable to other
settings with a variety of chlamydia prevalence. The
exception is that healthcare costs may differ between
settings, which should be considered when applying
these results to another location.
In addition to its strengths, several limitations to the
study should be mentioned. We utilized a static decision
analysis model that only accounted for 1 year of data.
This was done to avoid complications associated with
following the outcomes of pregnant women screened for
chlamydia after the pregnancy has ended, and risks to
the newborn and mother are greatly modified. It does,
however, preclude a dynamic study of infection, which
would account for changing prevalence and infection
rates as the modeled screening program progresses.
Additionally, as noted in previous studies, one aspect of
a screening program that leads to greater cost-
effectiveness is the ability to treat partners and subse-
quent decreased risk of reinfection. Due to a paucity of
Fig. 3 Monte Carlo Probabilistic Sensitivity Analysis: Figure shows number of times a certain cost per individual appeared in 100 iterations of 10,000
μ-simulations during the probabilistic sensitivity analysis when high impact variables were simultaneously randomly distributed across specific ranges
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data regarding rates of partner treatment as well as
asymptomatic chlamydial treatment, we were unable to
incorporate this variable into the model. The risk of ac-
quiring chlamydia-related sequelae is applied to all cases
of chlamydia at the time of infection and does not
account for the duration of the infection. Finally, there
exists uncertainty regarding the estimated rates of
chlamydia-related sequelae, which may lead to an over-
estimation of the cost-savings associated with a chla-
mydia screening program.
Interpretation
Increasingly accurate cost-benefit models are necessary
for properly evaluating the development, implementa-
tion and maintenance of screening programs. To more
accurately develop screening programs associated with
chlamydia more epidemiological data should be gathered
regarding three major variables that, if proper data
existed, would have improved the robustness of this
model’s results. These are the percent of chlamydia in-
fection that goes untreated, rates of asymptomatic chla-
mydia and rates of partner treatment coverage as a
result of screening. The addition of the variables to the
model would result in more accurate results, and the
model likely would have predicted increased cost savings
and averted morbidity associated with screening than
was presented. Future studies should focus on these epi-
demiological parameters.
Prior literature has reported that in low resource
countries with high chlamydia prevalence, such as Papua
New Guinea and many African countries where preva-
lence of infection in pregnant women may exceed 20%,
increased expenditures may be of particular concern
[26]. Implementation of a screening program may prove
particularly beneficial within a few years. Single dose
treatment with azithromycin is the current standard of
care [27]. The development of sensitive and affordable
point of care nucleic acid amplification tests (NAAT)
will make testing feasible in these regions [28]. This will
help further offset costs associated with screening, and
may even lead to net cost savings. Studies from Zambia
show that an integrated approach to antenatal screening
that builds on existing programs, such as those targeting
HIV prevention, can help manage both STI infections in
pregnancy, and help to overall increase antenatal attend-
ance. This will help further offset costs associated with
screening, especially when building a screening program
based on pre-existing programs, and may even lead to
net cost saving [8].
Conclusion
In summary, our finding and those of previous studies
support consideration that Chlamydia screening does
result in net expenditure, though with a significant
amount of averted morbidity [5, 8, 16, 21, 29],. Cur-
rently, the WHO does not recommend prenatal screen-
ing for chlamydia [30]. The data presented here can be
utilized by policy makers and public health researchers
to appropriately distribute funding and resources to-
wards where it would most benefit the target population.
Abbreviations
CDC: Centers for Disease Control and Prevention; NAAT: Nucleic acid
amplification tests; PID: Pelvic inflammatory disease; QALY: Quality adjusted
life year; STI: Sexually transmitted infections; US: United States; USD: United
States dollars; USPSTF: United States Preventive Services Task Force;
WTP: Willingness to pay
Funding
This study was not funded by any specific support.
Availability of data and materials
The datasets supporting the conclusions of this article are included within
the article.
Author contributions
JD Study design and analysis, data gathering, manuscript drafting and
editing; statistical analysis. KHS Data collection, data analysis. MRH Study
concept and design; manuscript editing and revision. SK Study design and
interpretation. TAS-N Study supervision, study design, manuscript prepar-
ation, and manuscript editing. Critical revision of manuscript. TAS-N and JD
had full access to all of the data in the study and take full responsibility for
the integrity of the data and the accuracy of the data analysis. All authors
read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
This study was exempt from ethical approval since we used existing data or
record collection from prior literature that contained non-identifiable data
about humans.
Received: 13 September 2016 Accepted: 7 February 2017
References
1. Centers for Disease Control and Prevention. Chlamydia screening among
sexually active young female enrollees of health plans–United States, 1999-
2001. MMWR Morb Mortal Wkly Rep. 2004;53(42):983–5.
2. Paschal AM, Oler-Manske J, Hsiao T. The role of local health departments in
providing sexually transmitted disease services and surveillance in rural
communities. J Community Health. 2011;36(2):204–10.
3. Owusu-Edusei Jr K, Chesson HW, Gift TL, et al. The estimated direct medical
cost of selected sexually transmitted infections in the United States, 2008.
Sex Transm Dis. 2013;40(3):197–201.
4. Stamm WE. Chlamydia trachomatis infections in the adult. In: Holmes KK,
Sparling PF, Stamm WE, et al., editors. Sexually transmitted diseases. 4th ed.
New York: McGraw- Hill; 2008. p. 575–93.
5. Ong JJ, Chen M, Hocking J, et al. Chlamydia screening for pregnant women
aged 16–25 years attending an antenatal service: a cost-effectiveness study.
BJOG. 2015;123:1194–202.
6. Honey E, Augood C, Templeton A, et al. Cost effectiveness of screening for
Chlamydia trachomatis: a review of published studies. Sex Transm Infect.
2002;78(6):406–12.
7. Norman JE, Wu O, Twaddle S, et al. An evaluation of economics and
acceptability of screening for Chlamydia trachomatis infection, in women
attending antenatal, abortion, colposcopy and family planning clinics in
Scotland. UK BJOG. 2004;111(11):1261–8.
8. Adachi K, Nielsen-Saines K, Klausner JD. Chlamydia trachomatis infection in
pregnancy: the global challenge of preventing adverse pregnancy and
Ditkowsky et al. BMC Infectious Diseases  (2017) 17:155 Page 8 of 9
infant outcomes in Sub-Saharan Africa and Asia. Biomed Res Int 2016;Art. ID
9315757:21. http://dx.doi.org/10.1155/2016/9315757, Accessed 17 Sept 2016.
9. Nettleman MD, Bell TA. Cost-effectiveness of prenatal testing for Chlamydia
trachomatis. Amer J Obstet Gynecol. 1991;164(5 Pt 1):1289–94.
10. Centers for Disease Control and Prevention. Recommendations for the
prevention and management of Chlamydia trachomatis infections, 1993.
Centers for Disease Control and Prevention. MMWR Recommendations and
Reports. 1993;42(RR-12):1–39.
11. LeFevre ML, U.S. Preventive Services Task Force Screening for Chlamydia
and gonorrhea. U.S. Preventive Services Task Force recommendation
statement. Ann Int Med. 2014;161(12):1–30.
12. Hammerschlag MR, Cummings C, Roblin PM, Williams TH, Delke I. Efficacy of
neonatal ocular prophylaxis for the prevention of chlamydial and
gonococcal conjunctivitis. N Engl J Med. 1989;320(12):769–72.
13. Centers for Disease Control and Prevention (CDC). National Center for HIV/
AIDS VH, STD, and TB Prevention. New York- 2015 State Health Profile. State
Profiles. 2015. http://www.cdc.gov/nchhstp/
14. Torrone E, Papp J, Weinstock H, Centers for Disease Conrol and Prevention
(CDC). Prevalence of Chlamydia trachomatis genital infection among
persons aged 14–39 Years — United States, 2007–2012. MMWR Morb
Mortal Wkly Rep. 2014;63(38):834–8.
15. Masek BJ, Arora N, Quinn N, et al. Performance of three nucleic acid
amplification tests for detection of Chlamydia trachomatis and Neisseria
gonorrhoeae by use of self-collected vaginal swabs obtained via an Internet-
based screening program. J Clin Microbiol. 2009;47(6):1663–7.
16. Huang W, Gaydos CA, Barnes MR, Jett-Goheen M, Blake DR. Cost-
effectiveness analysis of Chlamydia trachomatis screening via internet-based
self-collected swabs compared with clinic-based sample collection. Sex
Transm Dis. 2011;38(9):815–20.
17. Land JA, Van Bergen JE, Morre SA, Postma MJ. Epidemiology of Chlamydia
trachomatis infection in women and the cost-effectiveness of screening.
Hum Reprod Update. 2010;16(2):189–204.
18. Tanksley A, Cifu AS. Screening for Gonorrhea, Chlamydia, and Hepatitis B.
JAMA. 2016;315(12):1278–9.
19. Fan L, Owusu-Edusei Jr K, Schillie SF, Murphy TV. Cost-effectiveness of
testing hepatitis B-positive pregnant women for hepatitis B e antigen or
viral load. Obstet Gynecol. 2014;123(5):929–37.
20. Detels R, Green AM, Klausner JD, et al. The incidence and correlates of
symptomatic and asymptomatic Chlamydia trachomatis and Neisseria
gonorrhoeae infections in selected populations in five countries. Sex Transm
Dis. 2011;38(6):503–9.
21. Looker KJ, Wallace LA, Turner KM. Impact and cost-effectiveness of
chlamydia testing in Scotland: a mathematical modelling study. Theor Biol
Med Model. 2015;12:2.
22. Wong T, Kropp R, Mann J, editors. Canadian guidelines on sexually
transmitted infections. 2006th ed. Ottawa: Public Health Agency of Canada;
2006. Available from: http://dsp-psd.pwgsc.gc.ca/collection_2007/phac-aspc/
HP40-1-2006E.pdf.
23. Moore DL, MacDonald NE, Canadian Paediatric Society. Infectious Diseases
and Immunization Committee. Preventing opthalmia neonatorum. Pediatr
Child Health. 2015;20:93–6.
24. Rours GIJG, Smith-Norowitz TA, Ditkowsky J, et al. Cost-effectiveness analysis
of Chlamydia trachomatis screening in Dutch pregnant women. Path Global
Health. 2016. in press.
25. O’Higgins AC, Jackson V, Lawless M, et al. Screening for asymptomatic
urogenital Chlamydia trachomatis infection at a large Dublin maternity
hospital: results of a pilot study. Ir J Med Sci. 2016;11 [Epub ahead of print].
26. Vallely A, Page A, Dias S, et al. The prevalence of sexually transmitted
infections in Papua New Guinea: a systematic review and meta-analysis.
PLoS One. 2010;5(12):e15586.
27. Centers for Disease Control and Prevention. 2015 sexually transmitted diseases
treatment guidelines. MMWR Recomm Rep. 2015;64(No. RR-3):1–140.
28. Huang WGC, Barnes MR, Jett-Goheen M, Blake DR. Comparative
effectiveness of a rapid point-of-care test for detection of Chlamydia
trachomatis among women in a clinical setting. Sex Transm Infect. 2013;
89(2):108–14.
29. Blake DR, Maldeis N, Barnes MR, Hardick A, Quinn TC, Gaydos CA. Cost-
effectiveness of screening strategies for Chlamydia trachomatis using
cervical swabs, urine, and self-obtained vaginal swabs in a sexually
transmitted disease clinic setting. Sex Transm Dis. 2008;35(7):649–55.
30. World Health Organization. WHO Guidelines for the Treatment of Chlamydia
trachomatis. Geneva: World Health Organization; 2016.
31. Huang W, Gaydos CA, Barnes MR, et al. Cost effectivenss analysis of
Chlamydia trachomatis screening via internet-based self-collected swabs
compared with clinic-based sample collection. Sex Trasm Dis.
2011;38:815–20.
32. Lau C-Y, Qureshi AK. Azithromycin versus doxycycline for genital chlamydial
infections: a meta-analysis of randomized clinical trials. Sex Transm Dis.
2002;29(9):497–502.
33. Wiesenfeld HC, Hiller HS, Krohn MA, et al. Lower genital tract infection and
endometritis: insight into subclinical pelvic inflammatory disease. Obstet
Gynecol. 2002;100(3):456–63.
34. Baud D, Goy G, Jaton K, Osterheld M-C, Blumer S, Borel N, et al. Role of
Chlamydia trachomatis in miscarriage. Emerg Infect Dis. 2011;17(9):1630–5.
35. You JH, Chung TK. Expectant, medical or surgical treatment for
spontaneous abortion in first trimester of pregnancy: a cost analysis. Hum
Reprod. 2005;20(10):2873–8.
36. Liu B, Roberts CL, Clarke M, Jorm L, Hunt J, Ward J. Chlamydia and
gonorrhoea infections and the risk of adverse obstetric outcomes: a
retrospective cohort study. Sex Transmit Infect. 2013;89(8):672–8.
37. Hammerschlag MR, Kohlhoff SA. Chlamydia infections. In: Cherry JD,
Harrison GJ, Kaplan SL, Steinbach WJ, Hotez PJ, editors. Feigin and Cherry’s
textbook of pediatric infectious diseases, Chapter 193. Cambridge: Elsevier
Saundes Publishers; 2014. p. 2631–2645. e7.
38. Institute of Medicine (US). Committee on understanding premature birth
and assuring healthy outcomes. In: Behrman RE, Butler AS, editors. Preterm
birth: causes, consequences, and prevention. Washington DC: National
Academies Press; 2007. p. 389–429.
39. Menon S, Timms P, Allan JA, et al. Human and pathogen factors associated
with Chlamydia trachomatis-related infertility in women. Clin Microbiol Rev.
2015;28(4):969–85.
40. Chambers GM, Adamson GD, Eijkemans MJ. Acceptable cost for the patient
and society. Fertil Steril. 2013;100(2):319–27.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Ditkowsky et al. BMC Infectious Diseases  (2017) 17:155 Page 9 of 9
